Ratio Therapeutics
The Partner of Choice for Next-Generation Radiopharmaceutical Development
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- ratiotx.com
- Total Funding
- $50.0M
- Last Round
- $50.0M Series BJan 2024
About
Ratio Therapeutics is a Boston-based clinical-stage biopharmaceutical company developing next-generation targeted radiopharmaceuticals for the treatment of cancer. Founded in 2021 by John Babich, Ph.D. and Jack Hoppin, Ph.D., Ratio employs proprietary platforms including Trillium™—a tunable structural motif that enables compounds to reversibly bind albumin, modulating pharmacokinetics to improve tumor delivery while reducing off-target exposure. The company has raised over $90 million in total financing since its 2022 public launch, and operates a 19,000 sq ft headquarters and R&D facility in Boston's Design Center.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account